Pelvic Pain
Conditions
Brief summary
Endometriosis-associated pelvic pain (EAPP) is common in endometriosis and pain control is an important goal of long-term management. Non-steroidal anti-inflammatory drugs and oral contraception are the two first line therapies for endometriosis. High quality study about aspirin for the EAPP is absent. In this study, the investigators hypothesis that aspirin is effective in controlling EAPP. A randomized, open, and controlled study will be implemented. participants with EAPP with visual Analogue Scale(VAS）\>30 mm will be included and low dose aspirin（75mg/day） be prescribed. Yasmin(Drospirenone ethinyl estradiol tablet) will be used as positive control. The primary efficacy end points is the reduction of the pain score of EAPP at 24th week assessed with VAS score. Pelvic examination, sonography and blood test will be to performed to evaluate the lesion and coagulation function. The adverse event and medication compliance will be investigated. The aim of this study is to explore the efficacy and safety of low dose aspirin therapy in management of EAPP. This study will provide new options for the long-term management of endometriosis, which will help reduce the medical cost of endometriosis.
Detailed description
Endometriosis-associated pelvic pain (EAPP) is common in endometriosis and pain control is an important goal of long-term management. Non-steroidal anti-inflammatory drugs and oral contraception are the two first line therapies for endometriosis.However, there is currently a lack of high-quality clinical studies of nonsteroidal anti-inflammatory analgesic in controlling EAPP. The aim of this study is to explore the efficacy and safety of low dose aspirin therapy in management of EAPP. In this study, the investigators hypothesis that aspirin is effective in controlling EAPP. A randomized, open, and controlled study will be implemented. Subjects were recruited in strict accordance the inclusion and exclusion criteria at the outpatient clinic. Patients with EAPP with visual Analogue Scale(VAS:0-100mm）\>30mm will be included. Eligible subjects were randomized according to a computer-generated randomization schedule to to receive aspirin（75mg/day）or Yasmin(Drospirenone ethinyl estradiol tablet) in a ratio of 1:1. Specific doctors will be designated for the disease diagnosis and ultrasonic examination.The investigators were guided by EAPP pain score and drug use management. The primary efficacy end points is the reduction of the pain score of EAPP at 24th week assessed with VAS score. Pelvic examination, sonography and blood test will be to performed to evaluate the lesion and coagulation function. The specification of the CONSORT case report system will be implemented. Sample size assessment according equivalence study.Follow-up and loss cases were strictly controlled. A two-sided test will performed with beta=0.80 and αlpha=0.025. The expected loss rate is calculated at 15%. 220 cases will be enrolled with 110 cases in each group. The study will be accepted regular monitoring and inspection.
Interventions
DRUGAspirin
75mg, one time/day
1 table/day, 21 consecutive days, 28 days as a cycle of use
Sponsors
Women's Hospital School Of Medicine Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Dysmenorrhea or non-cyclical pelvic pain lasts for more than 3 months, and the VAS pain score is larger than 30mm * diagnosed as endometriosis * Willing to participate in clinical trials and sign informed consent
Exclusion criteria
* Those who have a clear surgical treatment plan due to various diseases within 6 months * Suspected or suffering from malignant tumor * Hemoglobin less than 8g/dl * women with contraindications to the use of aspirin or oral contraceptives * with other painful disease other than endometriosis * Active bleeding from other areas or undiagnosed abnormal vaginal bleeding * drug adminstration within 3 months including oral contraceptives, dienogest, Mirena or GnRH-a preparations, analgesics/Chinese medicines or proprietary Chinese medicines, etc. * Pregnancy status or breastfeeding * Any disease or symptom that may affect the implementation of the study or the interpretation of the results * Participate in other clinical trials at the same time
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| visual Analogue Scale | baseline , 12 weeks after treatment , and 24 weeks of treatment | a scale with 0-100 mm values, higher scores mean a worse outcome |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tenderness | baseline , 12 weeks of treatment , and 24 weeks of treatment | Tenderness during pelvic examination from 1 to 4,higher scores mean a worse outcome |
| size of endometrioid lesions | baseline , 12 weeks of treatment , and 24 weeks of treatment | endometrioid lesions detected by sonorgraphy |
| C reactive protein | baseline , 12 weeks of treatment , and 24 weeks of treatment | a biomarker of inflammation |
| carbohydrate antigen 125 | baseline , 12 weeks of treatment , and 24 weeks of treatment | a biomarker of endometriosis |
| platelets counts | baseline , 12 weeks of treatment , and 24 weeks of treatment | associated with inflammation and wound healing |
Countries
China
Contacts
Primary ContactZhengyun Chen, Master
Outcome results
None listed